Clinical development of curcumin in neurodegenerative disease

References

• Murugaiyah V, Mattson MP. Neurohormetic phytochemicals: An evolutionary-bioenergetic perspective. Neurochem Int 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Belkacemi A, Doggui S, Dao L, et al. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 2011;13:e34
   PubMed Web of Science ®Google Scholar
• Ray B, Lahiri DK. Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. Cur Opin Pharma 2009;9(4):434-44
   PubMed Web of Science ®Google Scholar
• Frautschy SA, Cole GM. Why pleiotropic interventions are Needed for Alzheimer’s disease. Mol Neurobiol 2010;41(2-3):392-409
   PubMed Web of Science ®Google Scholar
• Mancuso C, Siciliano R, Barone E, et al. Natural substances and Alzheimer’s disease: from preclinical studies to evidence based medicine. Biochim Biophys Acta 2012;1822(5):616-24
   PubMed Web of Science ®Google Scholar
• Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer’s disease in a rural community in India: the Indo-US study. Neurology 2001;57(6):985-9
   PubMedGoogle Scholar
• Chandra V, Ganguli M, Pandav R, et al. Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo-US study. Neurology 1998;51(4):1000-8
   PubMed Web of Science ®Google Scholar
• Ganguli M, Chandra V, Kamboh M, et al. Apolipoprotein e polymorphism and Alzheimer disease: the Indo-US cross-national dementia study. Arch Neurol 2000;57(6):824-30
   PubMedGoogle Scholar
• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-17
   PubMed Web of Science ®Google Scholar
• Tripathi M, Vibha D, Gupta P, et al. Risk factors of dementia in North India: a case-control study. Aging Ment Health 2012;16(2):228-35
   PubMed Web of Science ®Google Scholar
• Cheng KK, Yeung CF, Ho SW, et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J 2013;15(2):324-36
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Borrelli LA, Rozkalne A, et al. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007;102(4):1095-104
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892-901
   PubMed Web of Science ®Google Scholar
• Kim H, Park BS, Lee KG, et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005;53(22):8537-41
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742-50
   PubMed Web of Science ®Google Scholar
• Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J Pharmacol Exp Ther 2008;326(1):196-208
   PubMed Web of Science ®Google Scholar
• Yanagisawa D, Ibrahim NF, Taguchi H, et al. Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiol aging 2015;36(1):201-10
   PubMedGoogle Scholar
• Koronyo Y, Salumbides BC, Black KL, et al. Alzheimer’s disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. Neurodegener Dis 2012;10(1-4):285-93
   PubMed Web of Science ®Google Scholar
• Frost S, Kanagasingam Y, Macaulay L, et al. Retinal amyloid fluorescence imaging predicts cerebral amyloid burden and Alzheimer’s disease. Alzheimer’s Demen 2015;10(4 Supplement):33
   Google Scholar
• Ryu EK, Choe YS, Lee KH, et al. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 2006;49(20):6111-19
   PubMed Web of Science ®Google Scholar
• Zhang X, Tian Y, Li Z, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer’s disease. J Am Chem Soc 2013;135(44):16397-409
   PubMed Web of Science ®Google Scholar
• Landau M, Sawaya MR, Faull KF, et al. Towards a pharmacophore for amyloid. PLoS Biol 2011;9(6):e1001080
   PubMedGoogle Scholar
• Mohorko N, Repovs G, Popovic M, et al. Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol 2010;69(4):405-14
   PubMed Web of Science ®Google Scholar
• Mutsuga M, Chambers JK, Uchida K, et al. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer’s brain. J Vet Med Sci 2012;74(1):51-7
   PubMed Web of Science ®Google Scholar
• Brunden KR, Ballatore C, Crowe A, et al. Tau-directed drug discovery for Alzheimer’s disease and related tauopathies: A focus on tau assembly inhibitors. Exp Neurol 2010;223(2):304-10
   PubMedGoogle Scholar
• Ma QL, Zuo X, Yang F, et al. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 2013;288(6):4056-65
   PubMedGoogle Scholar
• Hickey MA, Gallant K, Zhu C, et al. A preclinical trial of curcumin in a knock-in mouse model (CAG140) of Huntington’s disease. Soc Neurosci 2005;31:90-5
   Google Scholar
• Caughey B, Raymond LD, Raymond GJ, et al. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 2003;77(9):5499-502
   PubMed Web of Science ®Google Scholar
• Pandey N, Strider J, Nolan WC, et al. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol 2008;115(4):479-89
   PubMed Web of Science ®Google Scholar
• Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006;97(1):105-15
   PubMed Web of Science ®Google Scholar
• Ahmad B, Lapidus LJ. Curcumin prevents aggregation in alpha-synuclein by increasing the reconfiguration rate. J Biol Chem 2012;287(12):9193-9
   PubMed Web of Science ®Google Scholar
• Miyasaka T, Yoshimura S, Saka A, et al. Curcumin Improves Tau-mediated Neuronal Dysfunction in Nematode. Alzheimer’s Demen 2010;6(4 Suppl):e27-8
   Google Scholar
• Calabrese V, Cornelius C, Mancuso C, et al. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 2008;33(12):2444-71
   PubMedGoogle Scholar
• Maiti P, Manna J, Hickey M, et al. Curcumin improves deficit of molecular chaperones and their client proteins in CAG140 knock-in, TauTg mice and 3xTg APPsw transgenic rat. Society for Neuroscience, New Orleans; 2012
   Google Scholar
• Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol aging 2001;22(6):993-1005
   PubMed Web of Science ®Google Scholar
• Cole GM, Morihara T, Lim GP, et al. NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models. Ann NY Acad Sci 2004;1035:68-84
   PubMed Web of Science ®Google Scholar
• Zhang L, Fiala M, Cashman J, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2006;10(1):1-7
   PubMed Web of Science ®Google Scholar
• Morgan D. Immunotherapy for Alzheimer’s disease. J Intern Med 2011;269(1):54-63
   PubMedGoogle Scholar
• King MD, McCracken DJ, Wade FM, et al. Attenuation of hematoma size and neurological injury with curcumin following intracerebral hemorrhage in mice. J Neurosurg 2011;115(1):116-23
   PubMedGoogle Scholar
• Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25(12):3032-40
   PubMed Web of Science ®Google Scholar
• Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-7
   PubMed Web of Science ®Google Scholar
• Xu YX, Pindolia KR, Janakiraman N, et al. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 1997 11(1):49-62
   Google Scholar
• Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 2007;19(3):469-74
   PubMed Web of Science ®Google Scholar
• Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270(42):24995-5000
   PubMed Web of Science ®Google Scholar
• Youn HS, Saitoh SI, Miyake K, Hwang DH. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 2006;72(1):62-9
   PubMedGoogle Scholar
• Wang HM, Zhao YX, Zhang S, et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 2010;20(4):1189-99
   PubMedGoogle Scholar
• Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005;128(Pt 6):1442-53
   PubMedGoogle Scholar
• Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67(6):953-66
   PubMed Web of Science ®Google Scholar
• Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991;51(3):813-19
   PubMed Web of Science ®Google Scholar
• Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2):cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004;25(9):1671-9
   PubMed Web of Science ®Google Scholar
• Lin R, Chen X, Li W, et al. Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci Lett 2008;440(3):344-7
   PubMed Web of Science ®Google Scholar
• Morihara T, Teter B, Yang F, et al. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer’s models. Neuropsychopharmacology 2005;30(6):1111-20
   PubMedGoogle Scholar
• Xiong Z, Hongmei Z, Lu S, et al. Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer’s Disease. Pharmacol Rep 2011;63(5):1101-8
   PubMed Web of Science ®Google Scholar
• Zhang C, Browne A, Child D, et al. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010;285(37):28472-80
   PubMedGoogle Scholar
• Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis 2004;6(4):367-77
   PubMedGoogle Scholar
• Soudamini KK, Unnikrishnan MC, Soni KB, et al. Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol 1992 36(4):239-43
   Google Scholar
• Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992;36(4):273-5
   PubMedGoogle Scholar
• Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol aging 2001;22:983-1
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999;20(5):911-14
   PubMedGoogle Scholar
• Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003;371(Pt 3):887-95
   PubMedGoogle Scholar
• Scapagnini G, Colombrita C, Amadio M, et al. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 2006;8(3-4):395-403
   PubMedGoogle Scholar
• Chen-Roetling J, Song W, Schipper HM, et al. Astrocyte over expression of heme oxygenase-1 improves outcome after intracerebral hemorrhage. Stroke;2015 46(4):1093-8
   Google Scholar
• Barone E, Butterfield AD. Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille’s heel? Neurobiol Dis 2015; Epub ahead of print
   PubMedGoogle Scholar
• Pickering AM, Linder RA, Zhang H, et al. Nrf2 dependent induction of proteasome and Pa28alphabeta regulator is required for adaptation to oxidative stress. J Biol Chem 2012;287(13):10021-31
   PubMed Web of Science ®Google Scholar
• Stridh MH, Correa F, Nodin C, et al. Enhanced glutathione efflux from astrocytes in culture by low extracellular Ca2+ and curcumin. Neurochem Res 2010;35(8):1231-8
   PubMedGoogle Scholar
• Singhal SS, Awasthi S, Pandya U, et al. The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. Toxicol Lett 1999;109(1-2):87-95
   PubMed Web of Science ®Google Scholar
• Nishinaka T, Ichijo Y, Ito M, et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 2007;170(3):238-47
   PubMedGoogle Scholar
• Jiao Y, Wilkinson JT, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med 2006;40(7):1152-60
   PubMed Web of Science ®Google Scholar
• Hegde ML, Hegde PM, Holthauzen LM, et al. Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem 2010;285(37):28812-25
   PubMedGoogle Scholar
• Sood PK, Nahar U, Nehru B. Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain. Neurotox Res 2011;20(4):351-61
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007;4(2):147-52
   PubMed Web of Science ®Google Scholar
• Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 2007;24(5):348-62
   PubMedGoogle Scholar
• Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003;28(6):809-22
   PubMed Web of Science ®Google Scholar
• Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005;8(3):247-68
   PubMed Web of Science ®Google Scholar
• Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009;29(28):9078-89
   PubMed Web of Science ®Google Scholar
• Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010;31(2):224-43
   PubMed Web of Science ®Google Scholar
• Kim SJ, Son TG, Park HR, et al. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 2008;283(21):14497-505
   PubMed Web of Science ®Google Scholar
• Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/beta-catenin pathway. ACS Nano 2014;8(1):76-103
   PubMed Web of Science ®Google Scholar
• Xu Y, Ku B, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007;1162:9-18
   PubMed Web of Science ®Google Scholar
• Wu A, Ying Z, Gomez-Pinilla F. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol 2006;197(2):309-17
   PubMed Web of Science ®Google Scholar
• Liu Y, Dargusch R, Maher P, et al. A broadly neuroprotective derivative of curcumin. J Neurochem 2008;105(4):1336-45
   PubMedGoogle Scholar
• Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10
   PubMedGoogle Scholar
• Aggarwal BB, Sundaram C, Malani N, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75
   PubMed Web of Science ®Google Scholar
• Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008;28(1):110-13
   PubMed Web of Science ®Google Scholar
• Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90(5):1011-15
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res Ther 2012;4(5):43
   PubMed Web of Science ®Google Scholar
• Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008;17(6):1411-17
   PubMed Web of Science ®Google Scholar
• Drobnic F, Riera J, Appendino G, et al. Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva(R)): a randomised, placebo-controlled trial. J Int Soc Sports Nutr 2014;11:31
   PubMed Web of Science ®Google Scholar
• 18-Month Study of Curcumin. Available from: https://www.clinicaltrials.gov/ct/show/NCT01383161
   Google Scholar
• Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013;71(6):1521-30
   PubMed Web of Science ®Google Scholar
• Frautschy SA, Begum AN, Gant DJ, et al. Efficacy of curcumin formulations in relation to systemic availability in the brain and different blood compartments in neuroinflammatory and AD models. Society For Neuroscience, Chicago; 2009
   Google Scholar
• Wang YY, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997;15(12):1867-6
   PubMed Web of Science ®Google Scholar
• Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64(4):353-6
   PubMed Web of Science ®Google Scholar
• Chan MM, Huang HI, Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998;55:1955-62
   PubMed Web of Science ®Google Scholar
• Antony B, Merina B, Iyer VS, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax): a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 2008;70(4):445-9
   PubMedGoogle Scholar
• Gota VS, Maru GB, Soni TG, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 2010;58(4):2095-9
   PubMed Web of Science ®Google Scholar
• Dadhaniya P, Patel C, Muchhara J, et al. Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies. Food Chem Toxicol 2011;49(8):1834-42
   PubMed Web of Science ®Google Scholar
• National Toxicology P. NTP toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1993;427:1-275
   PubMedGoogle Scholar
• Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 2007;56(6):509-14
   PubMed Web of Science ®Google Scholar
• Hishikawa N, Takahashi Y, Amakusa Y, et al. Effects of turmeric on Alzheimer’s disease with behavioral and psychological symptoms of dementia. Ayu 2012;33(4):499-504
   PubMedGoogle Scholar
• Curcumin and yoga therapy for those at risk for Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01811381
   Google Scholar
• Disilvestro RA, Joseph E, Zhao S, et al. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 2012;11(1):79
   PubMedGoogle Scholar
• Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 2014; Epub ahead of print
   PubMedGoogle Scholar